Inovio Pharmaceuticals, Inc. (INO)
NASDAQ: INO · Real-Time Price · USD
1.430
+0.010 (0.70%)
At close: Aug 1, 2025, 4:00 PM
1.448
+0.018 (1.27%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Chimerix Stock Forecast
INO's stock price has decreased by -86.59% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 5 analysts that cover Chimerix stock have a consensus rating of "Buy" and an average price target of $8.80, which forecasts a 515.38% increase in the stock price over the next year. The lowest target is $3.00 and the highest is $18.
Price Target: $8.80 (+515.38%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Chimerix stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 4 | 3 | 3 | 3 | 3 | 3 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Initiates $5 | Buy | Initiates | $5 | +249.65% | Jul 9, 2025 |
| RBC Capital | RBC Capital | Hold Reiterates $5 | Hold | Reiterates | $5 | +249.65% | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $15 → $13 | Buy | Maintains | $15 → $13 | +809.09% | May 14, 2025 |
| RBC Capital | RBC Capital | Hold Maintains $6 → $5 | Hold | Maintains | $6 → $5 | +249.65% | Mar 19, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $3 | Hold | Reiterates | $3 | +109.79% | Mar 19, 2025 |
Financial Forecast
Revenue This Year
79.79K
from 217.76K
Decreased by -63.36%
Revenue Next Year
16.51M
from 79.79K
Increased by 20,588.06%
EPS This Year
-2.05
from -3.95
EPS Next Year
-1.80
from -2.05
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 105,000 | 43.6M | 128.5M | ||
| Avg | 79,790 | 16.5M | 74.0M | ||
| Low | 58,800 | 784,000 | 38.0M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -51.8% | 54,538.4% | 678.5% | ||
| Avg | -63.4% | 20,588.1% | 348.5% | ||
| Low | -73.0% | 882.6% | 130.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.03 | -0.57 | -0.14 | ||
| Avg | -2.05 | -1.80 | -0.90 | ||
| Low | -2.66 | -2.80 | -1.73 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.